GOSS Stock Forecast & Price Target

Gossamer Bio has demonstrated a statistically significant improvement in the six-minute walk distance (6MWD) for its pipeline product, Seralutinib, with a notable placebo-adjusted enhancement of approximately 20–25 meters after 48 weeks, reflecting strong efficacy in treating pulmonary arterial hypertension (PAH). The continued improvement seen in the seralutinib group over a 72-week period across various metrics, including pulmonary vascular resistance (PVR) and functional capacity, suggests the potential for sustained therapeutic benefits, distinguishing it from traditional PAH treatments. Management's confidence in the clinical meaningfulness of these results, particularly the expected ≥30-meter improvement outcomes in future analyses, underscores an optimistic outlook for the company as it heads into a value-defining phase.

Gossamer Bio's financial outlook has deteriorated significantly, with FY32 total revenue estimates revised down to $324 million from an initial $993 million due to disappointing clinical trial results. The company's reliance on Seralutinib faces uncertainty, as the PROSERA data has not met expectations, raising concerns about the viability of a registrational path for the drug. Furthermore, the increase in the discount rate from 30% to 40% has further depressed the company’s target share price, reflecting the heightened risk associated with Gossamer Bio's current pipeline and market position.